Question 1

What is Cagrilintide?

Accepted Answer

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for weight management. Amylin is a hormone co-secreted with insulin from pancreatic beta cells that promotes satiety, slows gastric emptying, and suppresses glucagon secretion. Cagrilintide is being developed both as a standalone therapy and in combination with semaglutide under the name CagriSema. Phase 2 trials showed 11.

Question 2

What are the research benefits of Cagrilintide?

Accepted Answer

Research on Cagrilintide has investigated its potential effects in several areas, including: Novel amylin-based mechanism distinct from GLP-1 alone; 11.8% weight loss as monotherapy in Phase 2; Up to 17.1% combined with semaglutide (CagriSema); Weekly dosing convenience. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does Cagrilintide work?

Accepted Answer

Cagrilintide is an acylated analog of human amylin that binds to amylin receptors (AMY1 and AMY3) in the area postrema and other brain regions involved in appetite regulation. It enhances satiety signaling, slows gastric emptying, and suppresses post-prandial glucagon release. The combination with semaglutide (CagriSema) provides dual pathway weight loss through both amylin and GLP-1 receptor activation.

Question 4

What is the FDA/legal status of Cagrilintide?

Accepted Answer

Cagrilintide is currently in clinical trials and is not yet FDA-approved for general use. It may only be used in the context of approved clinical trial protocols. It is not available for general consumer purchase in the United States.

Question 5

What are the known risks or side effects of Cagrilintide?

Accepted Answer

Based on available research, Cagrilintide has been associated with the following in study settings: Nausea (dose-dependent); Injection site reactions; GI side effects (diarrhea, constipation); Still in clinical trials — full safety profile not established. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on Cagrilintide?

Accepted Answer

Published research on Cagrilintide can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "Cagrilintide" or its aliases (NN9838, CagriSema component) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

Cagrilintide

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer